Health
STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
Publication: STAT
Author: Ed Silverman
Source published: 20/11/2026, 00:00:00 UTC
Briefing created: 20/11/2026, 00:07:40 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 20/11/2026, 00:06:25 UTC.
Briefings
The House Select Committee on China reported that five major pharmaceutical firms—Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb—declined to launch new clinical trials in China's Xinjiang region or at military-affiliated hospitals. This decision follows a June investigation into these companies regarding intellectual property, military entanglements, and ethical standards at trial sites in sensitive areas.
Key points
- Five major pharmaceutical companies (Merck, Eli Lilly, AbbVie, Pfizer, Bristol Myers Squibb) declined to initiate new clinical trials in China's Xinjiang region or at military-affiliated hospitals.
- The House Select Committee on China conducted a June investigation into these five companies over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites in sensitive regions of the country.
Context
The House Select Committee on China last June opened investigations into five pharmaceutical companies (Merck, Eli Lilly, AbbVie, Pfizer, Bristol Myers Squibb) over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites in sensitive regions of the country. The companies indicated they would not initiate new clinical studies at sites linked to the People's Liberation Army.
Limitations
Evidence covers only five specific pharmaceutical companies and their refusal to start trials in Xinjiang or military hospitals. No specific dates for the refusal, exact number of affected hospitals, or reasons for the decline beyond security concerns are provided.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 20/11/2026, 00:07:40 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiewjzsymxnucketpypvauac4n5yy5ebfshqfwvgtdgtpcpgbpb3ri